Vericel Corporation (VCEL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 124 | 156 | 164 | 198 | 237 | 276 | 306 | 336 |
| Operating profit | $m | 11 | 18 | ||||||
| Net profit | $m | 3 | -7 | -17 | -3 | 10 | 17 | 24 | 28 |
| EPS reported | $ | 0.32 | 0.47 | ||||||
| Operating cashflow per share | $ | 1.03 | 1.37 | ||||||
| Capex per share | $ | 0.54 | 0.39 | ||||||
| FCF per share | $ | 0.49 | 0.97 | ||||||
| Free cash flow | $m | 25 | 50 | ||||||
| Net debt | $m | -123 | -162 | ||||||
| Book value equity | $m | 355 | 370 | ||||||
| Book value per share | $ | 6.81 | 7.27 | ||||||
| Number of shares | m | 52.07 | 50.93 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 112.53 | 84.89 | ||||||
| P/B LTM | x | 5.14 | 4.92 | ||||||
| P/S LTM | x | 6.59 | 5.95 | ||||||
| P/FCF LTM | x | 73.61 | 36.70 | ||||||
| EV/EBITDA LTM | x | 60.08 | 47.33 | ||||||
| EV/Sales LTM | x | 6.59 | 7.32 | ||||||
| Earnings Yield LTM | % | +0.89% | +1.18% | ||||||
| FCF Yield | % | +1.36% | +2.72% | ||||||
| Quality | |||||||||
| ROE | % | +4.66% | +6.91% | ||||||
| ROIC | % | +2.32% | +3.79% | ||||||
| Operating margin | % | +4.00% | +5.95% | ||||||
| Gross margin | % | +74.42% | +74.56% | ||||||
| FCF/Sales | % | +8.96% | +16.21% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +60.00% | +135.00% | ||||||
| Sales Growth YoY | % | +16.45% | +29.12% | ||||||
| Net Income Growth YoY | % | +59.41% | +133.75% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +144.39% | +303.52% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.25 | 0.54 | ||||||
| Net Debt/EBITDA | x | -0.06 | -0.85 | ||||||
| EBIT/Net interest | x | 7.10 | 28.49 | ||||||
| Net debt/market cap | % | +0.77% | +4.07% | ||||||
| Net debt/Equity | x | -0.35 | -0.44 | ||||||
| Gross debt/equity | x | 0.28 | 0.25 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free